Physician profile
Patrick M Chen
NPI 1598749616
$4,106.67
in general payments reported to CMS, 2019-2025
31 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $172 · 2021: $526 · 2022: $555 · 2023: $1,194 · 2024: $770 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,248.29 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $383.99 | 2019-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $336.02 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $278.96 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $271.57 | 2019-2023 | |
| Lilly USA, LLC | $241.17 | 2019-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $213.98 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $158.12 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $133.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $97.40 | 2019-2024 | Farxiga, Airsupra |
| Idorsia Pharmaceuticals US INC | $80.02 | 2023 | Quviviq |
| Allergan, INC. | $73.93 | 2019 | |
| Viiv Healthcare Company | $68.46 | 2023-2025 | Apretude |
| E.R. Squibb & Sons, L.L.C. | $67.52 | 2022-2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $58.53 | 2019-2023 | Dificid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $55.21 | 2022-2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $47.00 | 2019 | |
| Dexcom, INC. | $43.44 | 2022-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.51 | 2019 | |
| Myriad Women'S Health, INC. | $25.79 | 2023 | Myrisk |
| Shire North American Group INC | $24.98 | 2019 | |
| Boston Scientific Corporation | $22.33 | 2019 | |
| Embecta Corp. | $21.57 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.74 | 2022 | |
| Astellas Pharma US INC | $19.34 | 2019 | |
| Kyowa Kirin, INC. | $18.83 | 2024 | Nourianz |
| Bigfoot Biomedical INC | $17.60 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.55 | 2022 | |
| Horizon Therapeutics Plc | $11.96 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.